DOP Session 3

  • DOP Session 3, Strauss 3, Ground Floor, Congress Centre
  • 17:30-18:30 Digital Oral Presentation Session 3 – Old and new immunomodulators
    Room: Strauss 3, Ground Floor, Congress Centre
    Chairs:
    Krisztina Gecse, Amsterdam, The Netherlands
    Ailsa Hart, London, United Kingdom
      17:30-17:36 DOP019: Immunomodulators reduce the risk of surgery and hospitalization in Crohn’s Disease in a prospective European population-based inception cohort – the Epi-IBD cohort
    J. Burisch1, V. Andersen2, 3, S. Čuković-Čavka4, P.L. Lakatos5, R. D'Inca6, F. Magro7, 8, 9, N. Arebi10, L. Kievit11, I. Kaimakliotis12, D. Valpiani13, K.H. Katsanos14, Z. Vegh5, J.F. Dahlerup15, M. Fumery16, N. Pedersen17, J. Halfvarson18, E. Belousova 19, K.R. Nielsen20, S. Turcan21, P. Ellul22, L. Kupcinskas 23, P. Oksanen24, D. Duricova25, M. Giannotta26, A. Goldis27, V. Hernandez28, R. Salupere29, S. Odes30, E. Langholz31, P. Munkholm1, Epi-IBD study group
    1. North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark
    2. Viborg Regional Hospital, Medical Department, Viborg, Denmark
    3. Hospital of Southern Jutland, Medical Department, Aabenraa, Denmark
    4. University Hospital Center Zagreb, University of Zagreb School of Medicine, Division of Gastroenterology and Hepatology, Zagreb, Croatia
    5. Semmelweis University, 1st Department of Medicine, Budapest, Hungary
    6. Azienda Ospedaliera di Padova, Department of Surgery, Oncology and Gastroenterology, Padova, Italy
    7. University of Porto, Institute for molecular and cell biology, Porto, Portugal
    8. Hospital de São João, Department of Gastroenterology, Porto, Portugal
    9. Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto,
    Portugal
    10. St Mark's Hospital, Gastroenterology, London, United Kingdom
    11. Herning Central Hospital, Department of medicine, Herning, Denmark
    12. Nicosia Private practice, Nicosia Private practice, Nicosia, Cyprus
    13. Department of Gastroenterology and Digestive Endoscopy, Morgagni Hospital, Forli, Italy
    14. University Hospital, Ioannina, 1st Division of Internal Medicine and Hepato
    Gastroenterology Unit, Ioannina, Greece
    15. Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark
    16. Amiens University and Hospital, Epimad Registry, Gastroenterology Unit, Amiens, France
    17. Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark
    18. Faculty of Medicine and Health, Örebro University, Department of Gastronterology, Örebro, Sweden
    19. Moscow Regional Research Clinical Institute, Department of Gastroenterology, Moscow, Russian Federation
    20. The National Hospital of the Faroe Islands, Medical department, Tórshavn, Faroe Islands
    21. State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of
    22. Mater Dei Hospital, Division of Gastroenterology, L-Imsida, Malta
    23. Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania
    24. Tampere University Hospital, Department of Gastroenterology and
    Alimentary Tract Surgery, Tampere, Finland
    25. Charles University, IBD Center ISCARE, Prague, Czech Republic
    26. AOU Careggi Regional Referral Center for Inflammatory Bowel Disease, Gastroenterology Department, Florence, Italy
    27. University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania
    28. Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain
    29. Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia
    30. Soroka Medical Center and Ben Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel
    31. Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark
      17:36-17:42 DOP020: Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn’s Disease in the biological era
    B. Verstockt1, 2, L. Boets1, G. Van Assche1, 2, S. Vermeire1, 2, M. Ferrante1, 2 
    1. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 
    2. KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium
      17:42-17:48 DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s Disease: 10-year-follow-up data from the Swiss IBD cohort study
    P. Cernoch1, N. Fournier2, M. Scharl1, J. Zeitz3, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann7
    1. University Hospital Zurich, Division of Gastroenterology & Hepatology, Zurich, Switzerland
    2. University of Lausanne, IUMSP, Lausanne, Switzerland
    3. Klinik Hirslanden, Department of Gastroenterology, Zurich, Switzerland
    4. University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland
    5. CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland
    6. Center of Gastroenterology and Hepatology, Zurich, Switzerland
    7. University Hospital Zurich, Gastroenterology & Hepatology, Zurich, Switzerland
      17:48-17:54 DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trial
    J.E. Kreijne    1    , M.R. Lie1, G. Dijkstra2, M. Löwenberg3, G. van Assche4, R.L. West5, D. van Noord5, A.A. van der Meulen - de Jong6, B.E. Hansen1, 7, A.C. de Vries1, C.J. van der Woude1
    1. Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands
    2. University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, Netherlands
    3. Academic Medical Center Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands
    4. University Hospitals Leuven, KU Leuven, Gastroenterology, Leuven, Belgium
    5. Franciscus Hospital & Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, Netherlands
    6. Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands
    7. Toronto General Hospital, Center for Liver Disease, Toronto, Canada
      17:54-18:00 DOP023: Tofacitinib for the treatment of Ulcerative Colitis: Up to 4.4 years of safety data from global clinical trials
    W.J. Sandborn1, J. Panés2, G.R. D’Haens3, B.E. Sands4, C. Su5, M. Moscariello5, T.V. Jones5, R.D. Pedersen5, G.S. Friedman5, N. Lawendy5, G. Chan5
    1. University of California San Diego, Division of Gastroenterology, La Jolla, CA, United States
    2. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
    3. Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands
    4. Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States
    5. Pfizer Inc, Collegeville, PA, United States
       18:00-18:06 DOP024: Tofacitinib achieves symptomatic improvement within three days in moderately to severely active Ulcerative Colitis, regardless of prior tumour necrosis factor inhibitor treatment status: Results from OCTAVE induction 1 & 2
    S. Hanauer1, R. Panaccione2, S. Danese3, A. Cheifetz4, W. Reinisch5, P.D.R. Higgins6, D.A. Woodworth7, H. Zhang7, G.S. Friedman7, N. Lawendy7, D. Quirk7, C.I. Nduaka7, C. Su7
    1. Northwestern University, Evanston, IL, United States
    2. University of Calgary, Calgary, AB, Canada
    3. Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy
    4. Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Medicine and Division of Gastroenterology, Boston, MA, United States
    5. Medical University of Vienna, Dept Internal Medicine III, Vienna, Austria
    6. University of Michigan, Ann Arbor, MI, United States
    7. Pfizer Inc, Collegeville, PA, United States
       18:06-18:12 DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programme
    G.R. Lichtenstein1, M.A. Ciorba2, G. Rogler3, D. Quirk4, C.I. Nduaka4, R.D. Pedersen4, N. Lawendy4, G. Chan4, C. Su4, J. Panés51. Perelman School of Medicine of the University of Pennsylvania, Division of Gastroenterology, Philadelphia, PA, United States
    2. Washington University in Saint Louis, Division of Gastroenterology, Saint Louis, MO, United States
    3. University of Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland
    4. Pfizer Inc, Collegeville, PA, United States
    5. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
      18:12-18:18 DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE open
    B.E. Sands1, A.C. Moss2, A. Armuzzi3, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, K. Tsilkos8, N. Lawendy9, H. Zhang9, G.S. Friedman9, G. Chan9, D.W. Krichbaum8, C. Su9
    1. Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States
    2. Beth Israel Deaconess Medical Centre, Division of Gastroenterology, Boston, MA, United States
    3. Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy
    4. McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada
    5. The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom
    6. University of California San Diego, Division of Gastroenterology, La Jolla, CA, United States
    7. Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy
    8. Pfizer Inc, New York, NY, United States
    9. Pfizer Inc, Collegeville, PA, United States
      18:18-18:24 DOP027: Efficacy and safety of an additional eight weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib eigth-week induction non-responders
    B.G. Feagan1, M.C. Dubinsky2, M. Lukas3, D. Quirk4, C.I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, W. Wang4, G. Chan4, C. Su4
    1. Western University, Robarts Clinical Trials, London, ON, Canada
    2. Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, United States
    3. Charles University, Prague, Czech Republic
    4. Pfizer Inc, Collegeville, PA, United States